Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Core Viewpoint - Quoin Pharmaceuticals Ltd. has appointed Sally Lawlor as the new Chief Financial Officer to support the advancement of its lead product candidate, QRX003, through pivotal clinical studies and potential commercialization [1][2][4] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [5] - The company is committed to addressing unmet medical needs for patients and has a pipeline that includes four products targeting various rare and orphan indications [5] Leadership Changes - Sally Lawlor brings over 20 years of financial leadership experience from both public and private companies, as well as a Big Four accounting firm [2][3] - Dr. Michael Myers, CEO of Quoin, emphasized the importance of aligning the leadership structure to support the company's growth as it approaches the completion of QRX003 registrational trials [4] Product Development - Quoin is conducting two pivotal clinical studies for QRX003 in Netherton Syndrome, with full enrollment expected in early to mid-Q1 2026 across sites in the U.S., Europe, and the Middle East [4] - The company is also advancing development programs for Peeling Skin Syndrome and a novel topical rapamycin platform targeting a range of rare dermatologic diseases [4]